- June 21, 2021
- Posted by: Stratford Team
- Category: Business
PIOMBINO DESE, Italy–(BUSINESS WIRE)–Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its ordinary shares (the “Offering”). A portion of the ordinary shares will be issued and sold by the Company and a portion will be sold by its shareholder Stevanato Holding S.r.l. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The Offering is subject to market conditions, and there can be no assurance as to whether, or when, the Offering may be completed or as to the actual size or terms of the Offering. The Company intends to list its ordinary shares on the New…
